DAVID THOMAS

MEHLMAN CONSULTING, INC. · WASHINGTON, DC · registered since 2024

Registered · LDAActive

Send proposal →Contact →Claim this profile →

At a glance

Registered since

2024

Senate LDA system

Clients

124

last 3 years

Filings

356

33 agencies contacted

Activity

filings by quarter

Works on

Taxation/Internal Revenue Code 124 Medicare/Medicaid 112 Health Issues 111 Budget/Appropriations 91 Trade (domestic/foreign) 79 Computer Industry 55 Environment/Superfund 52 Consumer Issues/Safety/Products 43 Labor Issues/Antitrust/Workplace 33 Energy/Nuclear 33 Telecommunications 32 Pharmacy 31 Veterans 30 Defense 27 Financial Institutions/Investments/Securities 27 Manufacturing 27 Insurance 19 Homeland Security 18 Aviation/Airlines/Airports 17 Immigration 15 Banking 14 Communications/Broadcasting/Radio/TV 12 Housing 10 Copyright/Patent/Trademark 9 Small Business 8 Foreign Relations 7 Agriculture 7 Civil Rights/Civil Liberties 6 Utilities 6 Science/Technology 6 Retirement 6 Government Issues 5 Economics/Economic Development 5 Intelligence 4 Transportation 4 Accounting 3 Education 3 Clean Air and Water (quality) 3 Firearms/Guns/Ammunition 3 Fuel/Gas/Oil 3 Indian/Native American Affairs 3 Chemicals/Chemical Industry 3 Postal 3 Railroads 3 Automotive Industry 3 Animals 3 Trucking/Shipping 3 Food Industry (safety, labeling, etc.) 2 Law Enforcement/Crime/Criminal Justice 2 Marine/Maritime/Boating/Fisheries 2 Urban Development/Municipalities 1

Background

Government experience

CoS

Rep. Lofgren); Dir of Congressional Relations (FTC); Dep Dir for Legis Affairs (Office of VP Gore); Staff Asst (Senator Metzenbaum

Disclosed on LD-2 filings

Career

MEHLMAN CONSULTING, INC.

WASHINGTON, DC

2024 - present

Specific issues

Implementation of Inflation Reduction Act of 2022.

Health Issues · 2024 Q3

S. 775 - Increasing Transparency in Generic Drug Applications Act. Issues related to pharmaceutical manufacturing domestic supply chain, in H.R. 8070 - National Defense Authorization Act. S.2220 - PREVAIL Act. S.4097 - PERA Act.

Pharmacy · 2024 Q3

EPA's proposed interim decision draft risk assessment for ethylene oxide.

Environment/Superfund · 2024 Q4

Issues related to freight, rail, and supply chain.

Transportation · 2024 Q4

Federal lobbying related to tax policy.

Taxation/Internal Revenue Code · 2024 Q4

Issues pertaining to company programs related to workforce employment, benefits and training. Issues pertaining to the companys reinvention plans, initiatives and programs pertaining to workforce, sourcing, sustainability, civic engagement, education, veterans, economic development, entrepreneurship, safe and welcoming stores, and community resilience.

Labor Issues/Antitrust/Workplace · 2024 Q3